These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11063833)

  • 21. Animal models of myasthenia gravis.
    Christadoss P; Poussin M; Deng C
    Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1.
    Yang H; Tüzün E; Alagappan D; Yu X; Scott BG; Ischenko A; Christadoss P
    J Immunol; 2005 Aug; 175(3):2018-25. PubMed ID: 16034147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular immune response to acetylcholine receptors in murine experimental autoimmune myasthenia gravis: inhibition with monoclonal anti-I-A antibodies.
    Christadoss P; Lindstrom J; Talal N
    Cell Immunol; 1983 Oct; 81(1):1-8. PubMed ID: 6577968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic deficiency of estrogen receptor alpha fails to influence experimental autoimmune myasthenia gravis pathogenesis.
    Qi H; Li J; Allman W; Saini SS; Tüzün E; Wu X; Estes DM; Christadoss P
    J Neuroimmunol; 2011 May; 234(1-2):165-7. PubMed ID: 21481948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of peripheral blood acetylcholine receptor-binding B cells in experimental myasthenia gravis.
    Allman W; Saini SS; Tuzun E; Christadoss P
    Cell Immunol; 2011; 271(2):292-8. PubMed ID: 21861992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experimental autoimmune myasthenia gravis in naive non-obese diabetic (NOD/LtJ) mice: susceptibility associated with natural IgG antibodies to the acetylcholine receptor.
    Quintana FJ; Pitashny M; Cohen IR
    Int Immunol; 2003 Jan; 15(1):11-6. PubMed ID: 12502721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experimental autoimmune myasthenia gravis in mice expressing human immunoglobulin loci.
    Stassen MH; Meng F; Melgert E; Machiels BM; Im SH; Fuchs S; Gerritsen AF; van Dijk MA; van de Winkel JG; De Baets MH
    J Neuroimmunol; 2003 Feb; 135(1-2):56-61. PubMed ID: 12576224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis.
    Wang HB; Shi FD; Li H; van der Meide PH; Ljunggren HG; Link H
    Clin Immunol; 2000 May; 95(2):156-62. PubMed ID: 10779409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
    Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
    Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased expression of Src homology 2 domain-containing protein tyrosine phosphatase 1 reduces T cell activation threshold but not the severity of experimental autoimmune myasthenia gravis.
    Deng C; Wu B; Yang H; Hussain RZ; Lovett-Racke AE; Christadoss P; Racke MK
    J Neuroimmunol; 2003 May; 138(1-2):76-82. PubMed ID: 12742656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD1d(hi)CD5+ B cells expanded by GM-CSF in vivo suppress experimental autoimmune myasthenia gravis.
    Sheng JR; Quan S; Soliven B
    J Immunol; 2014 Sep; 193(6):2669-77. PubMed ID: 25135828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
    Xiao BG; Duan RS; Zhu WH; Lu CZ
    Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD4 costimulation is not required in a novel LPS-enhanced model of myasthenia gravis.
    Allman W; Qi H; Saini SS; Li J; Tuzun E; Christadoss P
    J Neuroimmunol; 2012 Aug; 249(1-2):1-7. PubMed ID: 22626443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
    Atassi MZ; Oshima M; Deitiker P
    Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ICOS is essential for the development of experimental autoimmune myasthenia gravis.
    Scott BG; Yang H; Tüzün E; Dong C; Flavell RA; Christadoss P
    J Neuroimmunol; 2004 Aug; 153(1-2):16-25. PubMed ID: 15265659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis.
    Wang YZ; Tian FF; Yan M; Zhang JM; Liu Q; Lu JY; Zhou WB; Yang H; Li J
    Clin Exp Immunol; 2014 May; 176(2):207-21. PubMed ID: 24387321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The susceptibility to experimental myasthenia gravis of STAT6-/- and STAT4-/- BALB/c mice suggests a pathogenic role of Th1 cells.
    Wang W; Ostlie NS; Conti-Fine BM; Milani M
    J Immunol; 2004 Jan; 172(1):97-103. PubMed ID: 14688314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis.
    Zhang GX; Xiao BG; Bai XF; van der Meide PH; Orn A; Link H
    J Immunol; 1999 Apr; 162(7):3775-81. PubMed ID: 10201893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MuSK induced experimental autoimmune myasthenia gravis does not require IgG1 antibody to MuSK.
    Küçükerden M; Huda R; Tüzün E; Yılmaz A; Skriapa L; Trakas N; Strait RT; Finkelman FD; Kabadayı S; Zisimopoulou P; Tzartos S; Christadoss P
    J Neuroimmunol; 2016 Jun; 295-296():84-92. PubMed ID: 27235354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating immune complexes augment severity of antibody-mediated myasthenia gravis in hypogammaglobulinemic RIIIS/J mice.
    Tüzün E; Scott BG; Yang H; Wu B; Goluszko E; Guigneaux M; Higgs S; Christadoss P
    J Immunol; 2004 May; 172(9):5743-52. PubMed ID: 15100321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.